{"ticker": {"uuid": "c28a1de4-d485-455d-b927-eaa8ea7d6ba9", "symbol": "RMD", "name": "ResMed Inc", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Medical Instruments & Supplies"}, "articles": [{"title": "ResMed Inc. stock rises Wednesday, outperforms market", "summary": "ResMed Inc. (RMD) stock increased by 2.88% to $198.57 on Wednesday, outperforming the broader market. This rise ended a three-day losing streak for the company's stock. The S&P 500 Index and the Dow Jones Industrial Average also saw gains on the same day.", "url": "https://www.marketwatch.com/data-news/resmed-inc-stock-rises-wednesday-outperforms-market-76305e46-2e826d0a1d14?mod=goog_fin_scmw", "source_name": "MarketWatch", "published_at": "2026-07-15T21:12:45", "published_display": "15 Jul 2026 21:12", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating", "summary": "Mizuho has adjusted its price target for ResMed (RMD) to $220 from the previous $235, while maintaining an Outperform rating on the stock. The article also briefly mentions Unity Software's Q4 financial results, reporting revenue of $609 million which beat estimates, and a quarte", "url": "https://www.moomoo.com/news/post/73020456/mizuho-adjusts-price-target-on-resmed-to-220-from-235?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-15T16:12:46", "published_display": "15 Jul 2026 16:12", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc (NYSE:RMD) Offers a Quality Dividend Built on Strong Profitability and Financial Health", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOVDM4TGNqalpWeWswTGZ1TTJEVnl0UzZyems4dzVnbUtqdGJhRkF6ZGt2WFFSM3VtWFgzdXdqY3BHY2NGam55akM4TDNCVHdvV2ltV2ctWjVUYUZGQVZFNFhNRzBQaG11aVlQd1ljUlZZSzFiVS1wOTQ0eWZyWjJaM0h3aFBWVXZrN2doZVdOekxIM0FjZGIxVVM4czJiTHQxMzZMQUk0OGFLSE1McVFZQzJGR1Z2TjhNbjgtaTl3ZEZ1LVFaTWdqUlVIYUZiQTY5ZDU3RmxaS3F3OEh6eWJj?oc=5", "source_name": "ChartMill", "published_at": "2026-07-15T12:50:28+00:00", "published_display": "15 Jul 2026 12:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Report: ResMed Inc.", "summary": "", "url": "https://finance.yahoo.com/m/f80535dc-80f5-39ea-9cd1-1ec2c74b3146/analyst-report%3A-resmed-inc..html", "source_name": "Morningstar Research", "published_at": "2026-07-14T23:34:24+00:00", "published_display": "14 Jul 2026 23:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Baird Adjusts ResMed Price Target to $217 From $225, Maintains Neutral Rating", "summary": "Baird has adjusted its price target for ResMed (RMD) to $217 from $225, while retaining a Neutral rating on the stock. This update comes amidst other recent analyst adjustments for ResMed, including a downgrade from Citigroup and price target changes from Jefferies, Jarden, Wells", "url": "https://www.marketscreener.com/news/baird-adjusts-resmed-price-target-to-217-from-225-maintains-neutral-rating-ce7f5edcd08cf025", "source_name": "www.marketscreener.com", "published_at": "2026-07-14T12:10:24", "published_display": "14 Jul 2026 12:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Price Target Cut to $235.00/Share From $270.00 by Citigroup", "summary": "Citigroup has significantly reduced its price target for ResMed (RMD) from $270.00 to $235.00 per share. This adjustment indicates a less optimistic outlook on the company's future stock performance by the financial institution.", "url": "https://www.moomoo.com/news/post/72859221/resmed-price-target-cut-to-235-00-share-from-270", "source_name": "Moomoo", "published_at": "2026-07-14T10:39:35", "published_display": "14 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Eli Lilly & Co (LLY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxPNFlVSVRhck1MV3Btc1VhZGpwNUJRRUtmdHRYUWVaUmdVR01SU1h4bGI4WWVMMGxMaC1ZQklhekswSUwxUGV6ZGdxMUhvVVJ4bm0zQ1B5bU1xVUhXRjlhQWtxSmlqY2F3c2VWd2Nhb0phMjRhRXpZT0NLVmR3alU0czY3eDlldXBnOUtQenF1R05fNjNpaXBNNnRaLUxhN3pJckI2Ym1oYWt2NmRReDBSYmt0bWVMUG9zM0ltMElRYUhhb2NMa1JWcXlkUmhHcmVsQzh1cG1BdkpNZUQxUkp4LTZRX0RfbjRZSDZFUW14UWlpUjd2cTdVQg?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T23:08:13+00:00", "published_display": "13 Jul 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cleveland Medical Devices Reports Favorable PTAB Outcomes in Five of Six ResMed IPR Challenges", "summary": "Cleveland Medical Devices Inc. announced favorable outcomes in five out of six inter partes review (IPR) challenges filed by ResMed against its patents before the Patent Trial and Appeal Board (PTAB). In four cases, the PTAB found ResMed did not establish unpatentability, and in ", "url": "https://www.prnewswire.com/news-releases/cleveland-medical-devices-reports-favorable-ptab-outcomes-in-five-of-six-resmed-ipr-challenges-302824198.html", "source_name": "PR Newswire", "published_at": "2026-07-13T20:23:48", "published_display": "13 Jul 2026 20:23", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc. stock falls Monday, underperforms market", "summary": "ResMed Inc. (RMD) shares dropped 2.63% to $198.50 on Monday, marking its second consecutive day of losses. This underperformance occurred during a generally poor trading session, with the S&P 500 Index (SPX) falling 0.79% and the Dow Jones Industrial Average (DJIA) declining 0.26", "url": "https://www.marketwatch.com/data-news/resmed-inc-stock-falls-monday-underperforms-market-9f53fb73-0a826f2f879f", "source_name": "MarketWatch", "published_at": "2026-07-13T16:58:00", "published_display": "13 Jul 2026 16:58", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citi Downgrades ResMed to Neutral From Buy; Price Target Is AU$34", "summary": "Citi has downgraded ResMed (RMD) from Buy to Neutral, setting a price target of AU$34. This adjustment follows ongoing challenges related to the GLP-1 drug class impact on sleep apnea device sales and increased competitive pressure from new Chinese market entrants. While the long", "url": "https://www.moomoo.com/news/post/72835997/citi-downgrades-resmed-to-neutral-from-buy-price-target-is?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T16:09:04", "published_display": "13 Jul 2026 16:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citigroup Downgrades ResMed to Neutral From Buy, Adjusts Price Target to $235 From $270", "summary": "Citigroup has downgraded ResMed (RMD) from a Buy rating to Neutral. Additionally, the firm adjusted its price target for ResMed, lowering it from $270 to $235. This change indicates a revised outlook on the stock's potential performance by Citigroup.", "url": "https://www.moomoo.com/news/post/72850765/citigroup-downgrades-resmed-to-neutral-from-buy-adjusts-price-target", "source_name": "Moomoo", "published_at": "2026-07-13T14:42:59", "published_display": "13 Jul 2026 14:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc. (RMD) Stock Analysis: Navigating a 25.60% Potential Upside Amidst Strong Healthcare Sector Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNT2I4UnNNYXVtZGVITHUyS1JmaGVrOTUtc2VTMXNxU2lIenMxTFVreXBfSlR4cmZ0LU1jRW1iMjFzc0FfdzdJbzFoLVFpdUE2RTB2ZkV3SksxQWlpWXN4aGhwTEVNNDBSNnJOZ1pxMGpoYk1PRVBaaDRZNDlKaTRtZEVLSDF4bDYzTTFpSFdiQ2NZQzlnaGRTV3JOLVB6ZU5QQkJnTnp2bU9CMlF5dHRBLVdxaHpVbnctbTRaaUxHX1ZPbVpPRTROVm5uMUlNUWdKQk1JVnBiN24zdjBRbUhMaWNQaU8wUGhCUmtJ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:22:58+00:00", "published_display": "13 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 US Healthcare Stocks Investors May Revisit As Inflation Pressures Build", "summary": "As inflation pressures build and crude/polypropylene costs rise, investors are looking for defensive large-cap stocks. This article identifies three U.S. healthcare stocks\u2014Abbott Laboratories (ABT), ResMed (RMD), and Stryker (SYK)\u2014that offer essential products and services, makin", "url": "https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/3-us-healthcare-stocks-investors-may-revisit-as-inflation-pr", "source_name": "Simply Wall Street", "published_at": "2026-07-13T08:47:00", "published_display": "13 Jul 2026 08:47", "sentiment": "positive", "sentiment_pct": 62, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Divestiture of MatrixCare presentation Summary", "summary": "ResMed (RMD) has signed an agreement to divest its MatrixCare business to Frazier Healthcare Partners for $490 million, with the transaction expected to close in Q1 FY27. This strategic move aims to sharpen ResMed's focus on its core growth areas: sleep, breathing, and connected ", "url": "https://quartr.com/events/resmed-inc-rmd-divestiture-of-matrixcare-presentation_3gA3vnTL", "source_name": "Quartr", "published_at": "2026-07-11T04:08:32", "published_display": "11 Jul 2026 04:08", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To ResMed (RMD) Selling MatrixCare To Refocus On Core Sleep Health", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T23:50:14+00:00", "published_display": "10 Jul 2026 23:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care", "summary": "Resmed has agreed to sell its MatrixCare business to Frazier Healthcare Partners, a move aimed at focusing on higher-growth opportunities in sleep health, breathing health, and connected home-based care. The divestiture is expected to close in the first quarter of fiscal 2027 and", "url": "https://sg.finance.yahoo.com/news/resmed-divests-matrixcare-business-sharpen-165100983.html", "source_name": "Market source", "published_at": "2026-07-10T17:51:00", "published_display": "10 Jul 2026 17:51", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc. stock falls Friday, underperforms market", "summary": "ResMed Inc. (RMD) saw its stock fall by 2.20% on Friday, closing at $203.87, despite a positive day for the broader market with both the S&P 500 and Dow Jones Industrial Average rising. The company's stock is now 30.61% below its 52-week high reached on August 22nd.", "url": "https://www.marketwatch.com/data-news/resmed-inc-stock-falls-friday-underperforms-market-065aaac9-b8127992046c?mod=goog_fin_scmw", "source_name": "MarketWatch", "published_at": "2026-07-10T16:58:00", "published_display": "10 Jul 2026 16:58", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Adjusts Price Target on ResMed to $225 From $240", "summary": "Jefferies has adjusted its price target on ResMed (RMD) to $225, down from $240. This change comes shortly after several other firms, including Jarden and Wells Fargo, also revised their price targets for the medical equipment company. ResMed recently announced the sale of its Ma", "url": "https://www.marketscreener.com/news/jefferies-adjusts-price-target-on-resmed-to-225-from-240-ce7f5eded081f725", "source_name": "marketscreener.com", "published_at": "2026-07-10T12:38:39", "published_display": "10 Jul 2026 12:38", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Sells MatrixCare To Refocus On Sleep And Respiratory Health", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/resmed-rmd-sells-matrixcare-refocus-111404508.html", "source_name": "Simply Wall St.", "published_at": "2026-07-10T11:14:04+00:00", "published_display": "10 Jul 2026 11:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Hold from Morgan Stanley", "summary": "Morgan Stanley analyst David Bailey maintained a Hold rating on Resmed Inc (RMD). Bailey, a 4-star analyst, covers the Healthcare sector and has an average return of 7.0%. Resmed Inc's latest earnings report shows a quarterly revenue of A$1.42 billion and a net profit of A$395.1 ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RMD-N/pressreleases/3220114/resmed-inc-chess-depositary-interests-on-a-ratio-of-10-cdis-per-ord-sh-rmd-gets-a-hold-from-morgan-stanley/", "source_name": "The Globe and Mail", "published_at": "2026-07-10T10:08:35", "published_display": "10 Jul 2026 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Macquarie", "summary": "Macquarie has maintained a Buy rating on Resmed Inc CHESS Depositary Interests (RMD) with a price target of A$46.60. This positive outlook is supported by recent earnings, which showed a quarterly revenue of A$1.42 billion and a net profit of A$395.1 million, an increase from the", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3216075/resmed-inc-chess-depositary-interests-on-a-ratio-of-10-cdis-per-ord-sh-rmd-gets-a-buy-from-macquarie/", "source_name": "The Globe and Mail", "published_at": "2026-07-10T01:01:10", "published_display": "10 Jul 2026 01:01", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan", "summary": "ResMed CEO Michael J. Farrell exercised 4,991 stock options and subsequently sold the same number of shares under a Rule 10b5-1 trading plan for approximately $218.55 per share. Following these transactions, Farrell's direct holdings in ResMed decreased slightly to 466,223 shares", "url": "https://www.tipranks.com/news/company-announcements/resmed-ceo-farrell-exercises-options-and-trims-stake-under-10b5-1-plan-2", "source_name": "TipRanks", "published_at": "2026-07-09T23:06:04", "published_display": "09 Jul 2026 23:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) After Russell Growth Index Exits Is The Undervalued Narrative Still Intact", "summary": "ResMed (RMD) has been dropped from several Russell growth indices, including the Russell 1000 Growth and Russell 3000 Growth, which has intensified scrutiny on the stock. Despite a recent share price decline of 15.9% year-to-date, Simply Wall St's analysis suggests ResMed is 21% ", "url": "https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-after-russell-growth-index-exits-is-the-undervalu", "source_name": "Simply Wall Street", "published_at": "2026-07-09T20:57:56", "published_display": "09 Jul 2026 20:57", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed's Q4 2026 Earnings: What to Expect", "summary": "ResMed Inc. (RMD) is set to announce its fiscal Q4 2026 earnings, with analysts expecting an adjusted EPS of $2.90, marking a 13.7% increase year-over-year. Despite the positive outlook for earnings, ResMed's shares have underperformed the broader market, falling 18.7% over the p", "url": "https://www.barchart.com/story/news/3207700/resmed-s-q4-2026-earnings-what-to-expect", "source_name": "Barchart.com", "published_at": "2026-07-09T15:21:39", "published_display": "09 Jul 2026 15:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Global Medical Ventilators Market Report 2025-2030 Just Released; Comprehensive Profiles of Getinge, Dr\u00e4gerwerk, Philips, Medtronic, and ResMed", "summary": "This article announces the release of a new report on the global medical ventilators market, covering the period from 2025 to 2030. The report includes comprehensive profiles of key industry players such as Getinge, Dr\u00e4gerwerk, Philips, Medtronic, and ResMed. It is a market analy", "url": "https://finance.yahoo.com/healthcare/articles/global-medical-ventilators-market-report-144300217.html", "source_name": "Market source", "published_at": "2026-07-09T14:15:50", "published_display": "09 Jul 2026 14:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed chairman & CEO Michael Farrell sells $1.09m in company stock", "summary": "ResMed's Chairman and CEO, Michael J. Farrell, sold $1.09 million worth of company stock through a Rule 10b5-1 trading plan, while simultaneously acquiring shares by exercising options. The transactions occurred on July 7, 2026, with Farrell selling 4,991 shares and exercising op", "url": "https://www.investing.com/news/insider-trading-news/resmed-chairman--ceo-michael-farrell-sells-109m-in-company-stock-93CH-4783842", "source_name": "Investing.com", "published_at": "2026-07-09T13:09:26", "published_display": "09 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 ResMed Inc For: 9 July By Investing.com", "summary": "This article announces the filing of a Form 4 for ResMed Inc. on July 9, 2026. It provides a brief update on this financial market activity without offering further details within the main content. The article is primarily a placeholder for the Form 4 information, accompanied by ", "url": "https://ca.investing.com/news/stock-market-news/form-4-resmed-inc-for-9-july-93CH-4727224", "source_name": "Investing.com Canada", "published_at": "2026-07-09T11:52:40", "published_display": "09 Jul 2026 11:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) CEO Michael Farrell sells 4,991 shares under 10b5-1 plan", "summary": "ResMed (RMD) CEO Michael J. Farrell exercised stock options for 4,991 shares and subsequently sold them in open-market transactions under a Rule 10b5-1 plan. The sale occurred at a weighted average price of $218.5475 per share, totaling approximately $1.09 million. Following thes", "url": "https://www.stocktitan.net/sec-filings/RMD/form-4-resmed-inc-insider-trading-activity-c093ab2a0e49.html", "source_name": "Stock Titan", "published_at": "2026-07-09T11:40:40", "published_display": "09 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc. stock falls Wednesday, underperforms market", "summary": "Shares of ResMed Inc. (RMD) decreased by 6.33% to $205.84 on Wednesday, breaking a four-day winning streak. This fall occurred during a generally negative trading session, with the S&P 500 Index dropping 0.28% and the Dow Jones Industrial Average falling 1.09%.", "url": "https://www.marketwatch.com/data-news/resmed-inc-stock-falls-wednesday-underperforms-market-17a06c3d-bc6a7f9736ae", "source_name": "MarketWatch", "published_at": "2026-07-08T20:30:26", "published_display": "08 Jul 2026 20:30", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ResMed Is Dropping 5.7%: RBC Capital Maintains Outperform", "summary": "ResMed Inc. shares fell 5.7% after two Wall Street banks, RBC Capital and Wells Fargo, slashed their price targets on the medical device maker due to dimmer prospects for its sleep apnea and respiratory care products. RBC Capital maintained an Outperform rating but significantly ", "url": "https://news.alphastreet.com/why-resmed-is-dropping-5-7-rbc-capital-maintains-outperform/", "source_name": "AlphaStreet", "published_at": "2026-07-08T19:13:41", "published_display": "08 Jul 2026 19:13", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc. focuses on sleep and respiratory care. Long-term demand supports the business model.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNYi1jTlM2aUEzX3JIRHBCNnR0THJXMlprT0pRTDhGTW50YXRLMEhyN0RfX3BiZndDLUl5RHdlbTZCSklvSzVKUngxVlpMeHlvbjAzclk0WmVXb3VfeEkxQ1B2WnZpWGQxNU56TkhMSHE2NUxvY3U5aXd3Q1huVlFaUmNua01naFh2ak1UWjlMTjE0aW82V1ZxSnplZE1JUlZmb1Nhczk4YzhSXzhuMnRCelZqbUlGMnlEV0hJejZFSU1vUQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-08T16:36:46+00:00", "published_display": "08 Jul 2026 16:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOZTlGSTFaNjhCSklCUlkwYXhxU0I4aVNRaFRsY2pZdVlETExQaWw3U2Y2Z2I3c0FUQWIzVjJGRnNpc0Q3MU5OOFdNaWtKTHFFNGpaR0tKVHFHaTNjQzRPS1M1UjhYa2lTX1FrQ3FHbUgwRnh0bUpBckg0d2ppMjFTS0c2MmxCMVlzZlI4VzJ3?oc=5", "source_name": "Market source", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed to sell software business MatrixCare for $490 million", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNT2NvNGJFSGdUVm5fODh6ZjhUTXFOeWhXLTkxWnVaTjJ0WC1HU3hraGJNcER0SDh0T184Z2U3RzdZQ0cxaFFiVDMza2h4Z091SHdBa015N044bThMb2JrSW1hcXgtY1RleGlvd0V6c0NzNFZEZ183LUhjaGlYZWRXbVJSa09Ba0lFZXdBNDJYakd0a1d5dUpkX0kxdGZYZWxXVkNCVi1VaEQ?oc=5", "source_name": "Reuters", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Resmed (RMD) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBuTFIwN0hsQ2dWMkNIOGRJRm8yYnVHSXhobXhTUjBqRjAwZkVkOEJRa0RKREdYUXZZTVdFRjA2ZEZMcFZUVkhvX0FiMXV5RFNXOXF4by1hR1h3Q2VlZnFBSWc5b2kyX1EzZEx3cFhxWFliaElKRUVlcHdQWDRwUTA?oc=5", "source_name": "Moomoo", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Stock And 2 Blue Chip Picks Retail Investors May Be Missing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQZFRRY3FXRUJFVlk5emlLWV9OWVhQa3lIdlo3dmJVUVAzU01wTXdHZF9pMTloVVYtS29udldDcmgzM1hKVXc2Qkl5RmxEYm5ZUnNyZTgtZEdaeU95cVlmY0h4cjhkSW1ZSWw2Z20wclJXdmh4cHUwd0N0Q0dDYllmM0dFOThoSmRiNC03bDZiVFdlV1dtWlB2dnc0cmZyQ2c0MEVHM2hTT0MwSHM1UmNuUVNudlFvbVcwdWlxaHdhaXBIVUEwZUZfb2Nn0gHPAUFVX3lxTFBxd2paWUVZTEItSTlDSGh0NC1QSHBhY2lZSTREUW05TWNuVXotN0Rac0RENnBrckduT3lxTkhmSHBlUkxpcHo1YjEwRnN5bEU5S0NId01iU1dTd29JMnhmS0dab1V4U2kzcXdHa3ludjBhWE9oTGxmcUtPOFZCX0dfR19IYnQxZWR6MmE1RS1LRXdmdG43N3k3MU9IUEl0dUlTSy1rejJuc0NieXowVDZocVJkd08zX3ZKU05PdFN3XzhQUzQ4TUFOd0tzVGhrcw?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ResMed (RMD) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNWHYxbFhKZk1JWFdDS2hLNUdURWp0R2xKbjlKTGdCTnI5ekI4SzNTd3RlRng3NERSeFB5SEs2SFdZUUhoSzJyZnNhZDJRRnUwWmJJbjRBRFpnRlVjMHdyVTM1ZmxiQVo1RHdpV2NwSWZkaGJhb0t1NnQ1cHA2ckNsQV90dGx3VlRFdmFuUDhIcDVadlJMLWJyRg?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc. focuses on sleep and respiratory care as a long-term growth story", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOLTFZQUZvWWp3NE9LS1FMWUcteUJ2aGpaQ1l0VHl4aTNiZVVxdm0xSGE3RWNUVWJIVDRVZVVid21jdVp1QndVQ2c4Q3BTc3huN2pBNERwQlgyNTJISTBud0RpRndVMTRuSzZ1VzUzQWZDY1I5ak5TZlRtQkc5ckFLU2Yzalh6eEV4bXFjbGJuTllMMWRXbTNKRGp6WllrWFR5ODlINHp3MU9TbFdxMVppOThJcHJNSHZPczFCOER0OEtYQkJBU2FFVA?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-01T16:39:31+00:00", "published_display": "01 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Stock Looks Cheap Even As The Market Stays Cautious", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPX1FEVlZYR1A3aUctMGtJMl81Unl3VzlVREw2UVViVTl0UlMxU2NsRGVYd0dvWXMyb1pTNDV3c1NpQS1wcm5hOFMyRy1TUS1yU3ZreWt4WlVCQ00zM2FtT1F1dWhhcjhHZmZmYUU4X1lCWUFBT3pKTTdYYldHQzFJLUp4N3JhOWIyX0FKbk1zSWN4MlJsbFpyXw?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Stock Looks Reasonable After A 23% Fall", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ResMed Inc. (RMD) Stock Still a Long-Term Winner as OSA Market Expansion Continues?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQM1hBQnZIR2dLZU9XZV9JVnp2ZnQydk1JM2prTUw1MkRvT3VmbnZGdGhFSFJTbThkQTJnR1pIWVNhVUJHd3RBUy1NMWVXWGtDbjM1RUVmUVh3MkcyaUxaN09ZQjFMZzVQMWJCZVNzSnZrY0xiVXZldVNSZXZGM0Q0VV9jRlJ1ZUZxODBDUXlUV0M?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Shares Downgraded: Trimmed Price Target Offers Some Comfort To Bulls", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNRFBKeE5SMy0zN2hsWGoyWUZxNEU5WUpGNjRsMkYyWGJaeDVheHlERTM3ajFFOXF5d0tIVEItZlJ6SkFHLXBZS0ZZLV9WeElpdE9vY0tBUEtOcG5vVDUzemRyV2NZRUZwSEFBSkpJcnhaaG9tTmdqd2V3VkxCaHNUQ3RqbGpmQ3dnTUFHbEd1bnB5bVJfYTEyejd4UWJDNlU5ejFDYWp3?oc=5", "source_name": "thebull.com.au", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ResMed (RMD) Shares Are Falling Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOOWJkbkxncDFGTnI1LWprZzVTU0J3R3UwVkV2LWxCa3FTY3ByZzF6ako3Y0cyUWR5aEptNDNOcXhXQkJrRjJqS1dKcHpvZm5RWU5KYXJCV2lCNzdNQkxMT0xQdUk5dFFpVnJ6Skc1UXUwZ3lMUDYzYTh6T0NGQlo4SEVHaDF2QnlQamZ6bE5sZ1pJTURwRUNFc0tn?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Stock Valuation Check After Mixed Returns And Undervaluation Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQa2NqQ0xVdGU5MUxDVUlBWnFSYXJpQVFuX1RTVmZMNmQ2NDZQNUtWRDQwMW1CTFlfbHg1YTZDb1pfNVk1dzNncnVjWDZabnNoUm1EX3hKTG5rRk1SSnQzN21ZMV9EWUlkT2N6ZTBENFctUGhneFJpQS1xOWNNS2liSVo0T3lRT3d1TUZsSE16dlh4QVFDNWtjeTNZdm5vQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ResMed Inc. (RMD) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOd0FyYk1qZnliWDRRMmc0bE9XYUdpUmtVN09aVTF0c3A2b2p5Q3huR0JnOHNPMWxGeDNxdVNHVmZ4YWtmTWV3aUYzS05BTDZGaHpRUy10UUlDeHlQNExWUkc1ZVN6ckxnUWYxV0NjeXFtVEE4ZXl0R1lYTmp1MzlpZDR3OGp4UUtUMklYaTBBWW1qbDhj?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess ResMed (RMD) After A 25% Share Price Slide?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPTzlaQmIyMkNsUnZhVnBhaWRiXzRyckh0SDFCc3B2M0xTYlpBSHdfMnhjWG9HYXZDbGh2MElIUnBCRmtLdDlRcjVkMkNzd3JLbGxIX1k2X0J2OXZjdGMzRTdLM0lsUHVFQmVGTjJBRWNLSEpSd1BaRkdLa3RpVWgtcEJPZ0dJWG44elA3Q0FweC01ek9KOXln?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (ASX:RMD) Q3 Results 2026: Is the ASX Healthcare Stock Back on Track?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQc3NZakEyaVpSUzZnX0htSmpOY3ViWFFBZlY5ZnI0eERxb2R0bE42bmt5ZWdRaEJPWFlZeV9OU0huNERtNjM5NkR5WG9WcDdkc2lUU2lNUTZSajhxakNrV3U4ZFJhNDlzdnBCOUhEWDFfdUtfYXY2cjZaQVhibjlQZ3Y5aXVpZ2dZVDd1ZXRVb1JRVmk0MXhBZGhPcjEwUUlNcmpkdWZNRE1SVEZIWnVN?oc=5", "source_name": "Kalkine", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc stock (AU000000RMD6): Sleep apnea and respiratory care leader posts strong growth outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQNGZ5THM5SU1TZW5Sc3N2azhsTjE5MHdleWFBS3lZamk1ZGlmbE8tSFFGNmpRVHhiMGc1T1ZwOU0tc0liODhZT3RUcWNrWDdDWnNtVERrTTBsOWc1WHpiNDllVUJFcmNGb1VUMlBCR3hMTDR1UEVfaTFOeTJjdVdvNFdoandmSDh3b2NqWGVjMG9xZVpNeGlnd3lpUWlNTXNDRC1OWXRGZnRjSkN0dm0telhjZTNPQ0xjOFFCTXhJMFRkVERnZ0M0?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Stock Is Down 22% in 2026: Here\u2019s Why Analysts Still Sees $256 Fair Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQMDVZWVJWWlA3RTF2dFpMNmwzTjlSVjdJdDlXRVFnSGVsTmRCaldSeHBmQXR5QmM2RVM5MnpJZjVxX0J3Sy0takpCUWRxQktnSHdlc05PYlpmYmphVjc1Tm9fLVJ5ZlJzYjRBaExmdVlZR211dUZ3cGdXaWxlOFBsZnBOc0hJVnJyNGhLN2FURWQ0LVZGbDhhM3ZBd0poR0ZzMS05Zg?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Surpasses Q3 Earnings and Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOMGFZRU5ReG52TGk2XzRoV3VhNVlwVnZNNThmVTc3eDFWZlV6SUtFUi04Y3hPUktrRTlRdEJNdVh4RW0zUmc4NENFdDZ4cTRBbXRsN0dKSGhuY1pyeFB5NDN6ZWMxYlk4MnhWVjVqeGpTTVBXbkhiQmtHajh3OXFtQV9MUGZNWXd0QzhEYnJyVmZ3RC14enpnaTktWUpyUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Resmed's Q3 Earnings on Deck: What's in Store for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQQ05lOWNMcFE2WXNCdGJCTjRTZkRkaUlDVXRzc0I3SklOal9KTGRpODZlSVRkZ1J5TWgwTWwtWDB4eFBMelI0OGNyWGVRVmVuaGV4UzhtWEE4WEdLWUtWTW9iRlpCNklNNWhNdDNvY2xBUUxqN1pxbXlCMWdET0VUZFpLbDdIRVFHckpGeUk1OGRWUElDT0lCSVBaWlpNYjBXOWFKWDhEd19DZnoyTXVSXzJoWFU?oc=5", "source_name": "TradingView", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Stock Trades Down, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE52UXpVc3NJY2huYndaSW8tNF90dHNMb2FYYl9WQ0kyYy1WaXpsaWhFSTVZdjc0SmVDRHNZczdEWWg4TVgxd095MVBETlJfUFFWR2Q5QjVjRGF4UUI5XzZhaXp1YnpFN0ExZU55bXlJSGZZZHhXODFTT3lqTFY0clE?oc=5", "source_name": "Market source", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock of the day: ResMed", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQbXM2V2ZOdjM5WDQ0OTlSZDVjYm4yMkRPZFZnWEFsZFpOSVdIRUcxVWQ5NDBVaE0zRW5NUE5pcC1sYmtQRjh0M3ZQSm1HT1JoRy10SExBaEs2Z0dKLXFqLUhXQVdUWDZZWUtocDliYTlNbC1VbG40VVN1bkdIa1NWUlZhbw?oc=5", "source_name": "ig.com", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Resmed's Q2 Earnings on Deck: What's in Store for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOaXFGaWZNbHNUeFBDb2YzNXBlcXdTTEs0OXNHWXA2d1VQZmtNa2NJQ2RkUVJfTXpldVAweGNpV2pfNi1qOHZWeEFneVQxZloyNHVNVkJoZmNEMEcxdUdJdTBkcGloN2ZQX3luNllYNjJETE9WdnZaV2pYUFl3QnVveUI4RXllZi1hRzgtVVA4ZUxpaUx6a0hmelJrZ2NGZGRKTDR5ajZVOXFnMDRiYmVvcnZ1OFo?oc=5", "source_name": "TradingView", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc. (NYSE:RMD) is favoured by institutional owners who hold 69% of the company", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-02T08:00:00+00:00", "published_display": "02 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX 200 healthcare stocks: ResMed, CSL, and Telix Pharmaceuticals in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQbThHc0xvdzNveVg0RlcyOWdLLXRQRGJQeU5SU0F3Q2xTalZqTmtUN2oxMUVDSVFJb3FKanR5S0M5TkVGUVI5ZllRT1VTYjQ0bkhrN01XN3p5Q0gxdEg3MkdPOERLdk9GMi1mWk00a1BVWERyLXJIaUI0WVZOSWh2V0JiSVA5VnZlYVlFVkNLT0RiOUhObm1hMFBweW81eUFhVVE?oc=5", "source_name": "ig.com", "published_at": "2025-09-23T07:00:00+00:00", "published_display": "23 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RESMED INC SEC 10-K Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNa01vb045LUtQbHNoMUxtVldSWU5KN1k1UjV1ckZfd1RtWElJOVU4VWlGbTZsUUlpV3ZvNEd6WV9wUTdNUXZFWlA3OTlacjl0dHpSWFRpenV4ZzNmaUc0RlpDdUNrUXJHUXJUQ1JpUXR5SlF0UGhlbmtwamxFVGJZMnc1RjFZNmNHQkNIYnk0ZjFyUQ?oc=5", "source_name": "TradingView", "published_at": "2025-08-08T07:00:00+00:00", "published_display": "08 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Full Year 2025 Earnings: EPS Beats Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQk5pQlA1cFVLT2FISEFTaVdndWRhdGp5aDlkX0VadkhlN0lBMmZDOTF6czFqRkZ5Q3ZCOVlqTG9aRlpMa1o0R3ZHUnJEUGVOdXNiQnY2R3ozVHotUzdNM1lIbTdHMHVEOUpXNUtzdkpEZ1lOcFhRd3pzLVhockVFak9DZHVjWGZkZlFEQzJPRnJubVZZcV9PZU15ZlBacHRqWEJtRWhOQTZPaHFIUUJodm1Gb2ozZmRw0gG-AUFVX3lxTE4zZFdJbzBSTzIxOGppaWdfVGhkRHVsb0tCV3RCVnd1b28xVWZkcXB5ZHZzZnhqZV9lUUVLTFFWRWc1cVhUUG5OTEhmcENQQ0sxejgzemtQOW5aZ24xLV9ac29BMkRkdEdvbmZ1TFZzVWZickp2ZnVtTnREeU5YRWpuYUJaOVJRR2RVTklBTTZVMFM2TUUyWFE3WHZVUzBlUi01WUYxRElQT2VuQ3YzcW9GSVBzMWduSzdzYjJadEE?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-03T07:00:00+00:00", "published_display": "03 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ResMed Inc. stock rises Wednesday, outperforms market", "summary": "ResMed Inc. (RMD) stock increased by 2.88% to $198.57 on Wednesday, outperforming the broader market. This rise ended a three-day losing streak for the company's stock. The S&P 500 Index and the Dow Jones Industrial Average also saw gains on the same day.", "url": "https://www.marketwatch.com/data-news/resmed-inc-stock-rises-wednesday-outperforms-market-76305e46-2e826d0a1d14?mod=goog_fin_scmw", "source_name": "MarketWatch", "published_at": "2026-07-15T21:12:45", "published_display": "15 Jul 2026 21:12", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating", "summary": "Mizuho has adjusted its price target for ResMed (RMD) to $220 from the previous $235, while maintaining an Outperform rating on the stock. The article also briefly mentions Unity Software's Q4 financial results, reporting revenue of $609 million which beat estimates, and a quarte", "url": "https://www.moomoo.com/news/post/73020456/mizuho-adjusts-price-target-on-resmed-to-220-from-235?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-15T16:12:46", "published_display": "15 Jul 2026 16:12", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc (NYSE:RMD) Offers a Quality Dividend Built on Strong Profitability and Financial Health", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxOVDM4TGNqalpWeWswTGZ1TTJEVnl0UzZyems4dzVnbUtqdGJhRkF6ZGt2WFFSM3VtWFgzdXdqY3BHY2NGam55akM4TDNCVHdvV2ltV2ctWjVUYUZGQVZFNFhNRzBQaG11aVlQd1ljUlZZSzFiVS1wOTQ0eWZyWjJaM0h3aFBWVXZrN2doZVdOekxIM0FjZGIxVVM4czJiTHQxMzZMQUk0OGFLSE1McVFZQzJGR1Z2TjhNbjgtaTl3ZEZ1LVFaTWdqUlVIYUZiQTY5ZDU3RmxaS3F3OEh6eWJj?oc=5", "source_name": "ChartMill", "published_at": "2026-07-15T12:50:28+00:00", "published_display": "15 Jul 2026 12:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Report: ResMed Inc.", "summary": "", "url": "https://finance.yahoo.com/m/f80535dc-80f5-39ea-9cd1-1ec2c74b3146/analyst-report%3A-resmed-inc..html", "source_name": "Morningstar Research", "published_at": "2026-07-14T23:34:24+00:00", "published_display": "14 Jul 2026 23:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Baird Adjusts ResMed Price Target to $217 From $225, Maintains Neutral Rating", "summary": "Baird has adjusted its price target for ResMed (RMD) to $217 from $225, while retaining a Neutral rating on the stock. This update comes amidst other recent analyst adjustments for ResMed, including a downgrade from Citigroup and price target changes from Jefferies, Jarden, Wells", "url": "https://www.marketscreener.com/news/baird-adjusts-resmed-price-target-to-217-from-225-maintains-neutral-rating-ce7f5edcd08cf025", "source_name": "www.marketscreener.com", "published_at": "2026-07-14T12:10:24", "published_display": "14 Jul 2026 12:10", "sentiment": "negative", "sentiment_pct": 35, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Price Target Cut to $235.00/Share From $270.00 by Citigroup", "summary": "Citigroup has significantly reduced its price target for ResMed (RMD) from $270.00 to $235.00 per share. This adjustment indicates a less optimistic outlook on the company's future stock performance by the financial institution.", "url": "https://www.moomoo.com/news/post/72859221/resmed-price-target-cut-to-235-00-share-from-270", "source_name": "Moomoo", "published_at": "2026-07-14T10:39:35", "published_display": "14 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Eli Lilly & Co (LLY)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxPNFlVSVRhck1MV3Btc1VhZGpwNUJRRUtmdHRYUWVaUmdVR01SU1h4bGI4WWVMMGxMaC1ZQklhekswSUwxUGV6ZGdxMUhvVVJ4bm0zQ1B5bU1xVUhXRjlhQWtxSmlqY2F3c2VWd2Nhb0phMjRhRXpZT0NLVmR3alU0czY3eDlldXBnOUtQenF1R05fNjNpaXBNNnRaLUxhN3pJckI2Ym1oYWt2NmRReDBSYmt0bWVMUG9zM0ltMElRYUhhb2NMa1JWcXlkUmhHcmVsQzh1cG1BdkpNZUQxUkp4LTZRX0RfbjRZSDZFUW14UWlpUjd2cTdVQg?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T23:08:13+00:00", "published_display": "13 Jul 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cleveland Medical Devices Reports Favorable PTAB Outcomes in Five of Six ResMed IPR Challenges", "summary": "Cleveland Medical Devices Inc. announced favorable outcomes in five out of six inter partes review (IPR) challenges filed by ResMed against its patents before the Patent Trial and Appeal Board (PTAB). In four cases, the PTAB found ResMed did not establish unpatentability, and in ", "url": "https://www.prnewswire.com/news-releases/cleveland-medical-devices-reports-favorable-ptab-outcomes-in-five-of-six-resmed-ipr-challenges-302824198.html", "source_name": "PR Newswire", "published_at": "2026-07-13T20:23:48", "published_display": "13 Jul 2026 20:23", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc. stock falls Monday, underperforms market", "summary": "ResMed Inc. (RMD) shares dropped 2.63% to $198.50 on Monday, marking its second consecutive day of losses. This underperformance occurred during a generally poor trading session, with the S&P 500 Index (SPX) falling 0.79% and the Dow Jones Industrial Average (DJIA) declining 0.26", "url": "https://www.marketwatch.com/data-news/resmed-inc-stock-falls-monday-underperforms-market-9f53fb73-0a826f2f879f", "source_name": "MarketWatch", "published_at": "2026-07-13T16:58:00", "published_display": "13 Jul 2026 16:58", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citi Downgrades ResMed to Neutral From Buy; Price Target Is AU$34", "summary": "Citi has downgraded ResMed (RMD) from Buy to Neutral, setting a price target of AU$34. This adjustment follows ongoing challenges related to the GLP-1 drug class impact on sleep apnea device sales and increased competitive pressure from new Chinese market entrants. While the long", "url": "https://www.moomoo.com/news/post/72835997/citi-downgrades-resmed-to-neutral-from-buy-price-target-is?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T16:09:04", "published_display": "13 Jul 2026 16:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citigroup Downgrades ResMed to Neutral From Buy, Adjusts Price Target to $235 From $270", "summary": "Citigroup has downgraded ResMed (RMD) from a Buy rating to Neutral. Additionally, the firm adjusted its price target for ResMed, lowering it from $270 to $235. This change indicates a revised outlook on the stock's potential performance by Citigroup.", "url": "https://www.moomoo.com/news/post/72850765/citigroup-downgrades-resmed-to-neutral-from-buy-adjusts-price-target", "source_name": "Moomoo", "published_at": "2026-07-13T14:42:59", "published_display": "13 Jul 2026 14:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc. (RMD) Stock Analysis: Navigating a 25.60% Potential Upside Amidst Strong Healthcare Sector Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNT2I4UnNNYXVtZGVITHUyS1JmaGVrOTUtc2VTMXNxU2lIenMxTFVreXBfSlR4cmZ0LU1jRW1iMjFzc0FfdzdJbzFoLVFpdUE2RTB2ZkV3SksxQWlpWXN4aGhwTEVNNDBSNnJOZ1pxMGpoYk1PRVBaaDRZNDlKaTRtZEVLSDF4bDYzTTFpSFdiQ2NZQzlnaGRTV3JOLVB6ZU5QQkJnTnp2bU9CMlF5dHRBLVdxaHpVbnctbTRaaUxHX1ZPbVpPRTROVm5uMUlNUWdKQk1JVnBiN24zdjBRbUhMaWNQaU8wUGhCUmtJ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:22:58+00:00", "published_display": "13 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 US Healthcare Stocks Investors May Revisit As Inflation Pressures Build", "summary": "As inflation pressures build and crude/polypropylene costs rise, investors are looking for defensive large-cap stocks. This article identifies three U.S. healthcare stocks\u2014Abbott Laboratories (ABT), ResMed (RMD), and Stryker (SYK)\u2014that offer essential products and services, makin", "url": "https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/3-us-healthcare-stocks-investors-may-revisit-as-inflation-pr", "source_name": "Simply Wall Street", "published_at": "2026-07-13T08:47:00", "published_display": "13 Jul 2026 08:47", "sentiment": "positive", "sentiment_pct": 62, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Divestiture of MatrixCare presentation Summary", "summary": "ResMed (RMD) has signed an agreement to divest its MatrixCare business to Frazier Healthcare Partners for $490 million, with the transaction expected to close in Q1 FY27. This strategic move aims to sharpen ResMed's focus on its core growth areas: sleep, breathing, and connected ", "url": "https://quartr.com/events/resmed-inc-rmd-divestiture-of-matrixcare-presentation_3gA3vnTL", "source_name": "Quartr", "published_at": "2026-07-11T04:08:32", "published_display": "11 Jul 2026 04:08", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To ResMed (RMD) Selling MatrixCare To Refocus On Core Sleep Health", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPS3NHWDVrSzhXRXJsbldsaEIxMUFXWFgxMVJnTzZ3S1ZHaUhYb2t2bzlhM3VGLXhXMUh5YVFLcmx4UEZia19uMFY2R291MjNpNW1hdUF6cDhnZGhpaG03ckIzaktneWtmd2w3bFRfMzlFQXprSUpMY1JJZ0h0RmZ4UlE4UXVUT1U3SDE3OFRmc1VKZ0d2QWpBazZLV255dnBsVzU1bkpWZ253VWMzM0RaMUoxS2Z2ZF9kQmRkaEFncTbSAcYBQVVfeXFMTTFUam5MVTh2bUJUYndDNmtKTlZDR3haSk1MS0RHQ0h6cVhFaHZlQ0w2MnlTQlFKTjU4dzZDTGxKVkJ2cms2cEhpZEVhMlIxREN0Q1JWQ21idTZrZlVNOWZrbm1GYXdpemFadjg3dkptTkpqM2w3MXNiVU1IdWdjTVRkYTgxa3diUFk0dlRGemM4QlFWak1VeFRYQndNT1Rwbld6Ui1PQUJTN0hPczZ1cG12TzRtbGZGcThsZ2V3QU94d0VUc3hR?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T23:50:14+00:00", "published_display": "10 Jul 2026 23:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care", "summary": "Resmed has agreed to sell its MatrixCare business to Frazier Healthcare Partners, a move aimed at focusing on higher-growth opportunities in sleep health, breathing health, and connected home-based care. The divestiture is expected to close in the first quarter of fiscal 2027 and", "url": "https://sg.finance.yahoo.com/news/resmed-divests-matrixcare-business-sharpen-165100983.html", "source_name": "Market source", "published_at": "2026-07-10T17:51:00", "published_display": "10 Jul 2026 17:51", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc. stock falls Friday, underperforms market", "summary": "ResMed Inc. (RMD) saw its stock fall by 2.20% on Friday, closing at $203.87, despite a positive day for the broader market with both the S&P 500 and Dow Jones Industrial Average rising. The company's stock is now 30.61% below its 52-week high reached on August 22nd.", "url": "https://www.marketwatch.com/data-news/resmed-inc-stock-falls-friday-underperforms-market-065aaac9-b8127992046c?mod=goog_fin_scmw", "source_name": "MarketWatch", "published_at": "2026-07-10T16:58:00", "published_display": "10 Jul 2026 16:58", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Adjusts Price Target on ResMed to $225 From $240", "summary": "Jefferies has adjusted its price target on ResMed (RMD) to $225, down from $240. This change comes shortly after several other firms, including Jarden and Wells Fargo, also revised their price targets for the medical equipment company. ResMed recently announced the sale of its Ma", "url": "https://www.marketscreener.com/news/jefferies-adjusts-price-target-on-resmed-to-225-from-240-ce7f5eded081f725", "source_name": "marketscreener.com", "published_at": "2026-07-10T12:38:39", "published_display": "10 Jul 2026 12:38", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Sells MatrixCare To Refocus On Sleep And Respiratory Health", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/resmed-rmd-sells-matrixcare-refocus-111404508.html", "source_name": "Simply Wall St.", "published_at": "2026-07-10T11:14:04+00:00", "published_display": "10 Jul 2026 11:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Hold from Morgan Stanley", "summary": "Morgan Stanley analyst David Bailey maintained a Hold rating on Resmed Inc (RMD). Bailey, a 4-star analyst, covers the Healthcare sector and has an average return of 7.0%. Resmed Inc's latest earnings report shows a quarterly revenue of A$1.42 billion and a net profit of A$395.1 ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RMD-N/pressreleases/3220114/resmed-inc-chess-depositary-interests-on-a-ratio-of-10-cdis-per-ord-sh-rmd-gets-a-hold-from-morgan-stanley/", "source_name": "The Globe and Mail", "published_at": "2026-07-10T10:08:35", "published_display": "10 Jul 2026 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Macquarie", "summary": "Macquarie has maintained a Buy rating on Resmed Inc CHESS Depositary Interests (RMD) with a price target of A$46.60. This positive outlook is supported by recent earnings, which showed a quarterly revenue of A$1.42 billion and a net profit of A$395.1 million, an increase from the", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3216075/resmed-inc-chess-depositary-interests-on-a-ratio-of-10-cdis-per-ord-sh-rmd-gets-a-buy-from-macquarie/", "source_name": "The Globe and Mail", "published_at": "2026-07-10T01:01:10", "published_display": "10 Jul 2026 01:01", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan", "summary": "ResMed CEO Michael J. Farrell exercised 4,991 stock options and subsequently sold the same number of shares under a Rule 10b5-1 trading plan for approximately $218.55 per share. Following these transactions, Farrell's direct holdings in ResMed decreased slightly to 466,223 shares", "url": "https://www.tipranks.com/news/company-announcements/resmed-ceo-farrell-exercises-options-and-trims-stake-under-10b5-1-plan-2", "source_name": "TipRanks", "published_at": "2026-07-09T23:06:04", "published_display": "09 Jul 2026 23:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) After Russell Growth Index Exits Is The Undervalued Narrative Still Intact", "summary": "ResMed (RMD) has been dropped from several Russell growth indices, including the Russell 1000 Growth and Russell 3000 Growth, which has intensified scrutiny on the stock. Despite a recent share price decline of 15.9% year-to-date, Simply Wall St's analysis suggests ResMed is 21% ", "url": "https://simplywall.st/stocks/us/healthcare/nyse-rmd/resmed/news/resmed-rmd-after-russell-growth-index-exits-is-the-undervalu", "source_name": "Simply Wall Street", "published_at": "2026-07-09T20:57:56", "published_display": "09 Jul 2026 20:57", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed's Q4 2026 Earnings: What to Expect", "summary": "ResMed Inc. (RMD) is set to announce its fiscal Q4 2026 earnings, with analysts expecting an adjusted EPS of $2.90, marking a 13.7% increase year-over-year. Despite the positive outlook for earnings, ResMed's shares have underperformed the broader market, falling 18.7% over the p", "url": "https://www.barchart.com/story/news/3207700/resmed-s-q4-2026-earnings-what-to-expect", "source_name": "Barchart.com", "published_at": "2026-07-09T15:21:39", "published_display": "09 Jul 2026 15:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Global Medical Ventilators Market Report 2025-2030 Just Released; Comprehensive Profiles of Getinge, Dr\u00e4gerwerk, Philips, Medtronic, and ResMed", "summary": "This article announces the release of a new report on the global medical ventilators market, covering the period from 2025 to 2030. The report includes comprehensive profiles of key industry players such as Getinge, Dr\u00e4gerwerk, Philips, Medtronic, and ResMed. It is a market analy", "url": "https://finance.yahoo.com/healthcare/articles/global-medical-ventilators-market-report-144300217.html", "source_name": "Market source", "published_at": "2026-07-09T14:15:50", "published_display": "09 Jul 2026 14:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed chairman & CEO Michael Farrell sells $1.09m in company stock", "summary": "ResMed's Chairman and CEO, Michael J. Farrell, sold $1.09 million worth of company stock through a Rule 10b5-1 trading plan, while simultaneously acquiring shares by exercising options. The transactions occurred on July 7, 2026, with Farrell selling 4,991 shares and exercising op", "url": "https://www.investing.com/news/insider-trading-news/resmed-chairman--ceo-michael-farrell-sells-109m-in-company-stock-93CH-4783842", "source_name": "Investing.com", "published_at": "2026-07-09T13:09:26", "published_display": "09 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 ResMed Inc For: 9 July By Investing.com", "summary": "This article announces the filing of a Form 4 for ResMed Inc. on July 9, 2026. It provides a brief update on this financial market activity without offering further details within the main content. The article is primarily a placeholder for the Form 4 information, accompanied by ", "url": "https://ca.investing.com/news/stock-market-news/form-4-resmed-inc-for-9-july-93CH-4727224", "source_name": "Investing.com Canada", "published_at": "2026-07-09T11:52:40", "published_display": "09 Jul 2026 11:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) CEO Michael Farrell sells 4,991 shares under 10b5-1 plan", "summary": "ResMed (RMD) CEO Michael J. Farrell exercised stock options for 4,991 shares and subsequently sold them in open-market transactions under a Rule 10b5-1 plan. The sale occurred at a weighted average price of $218.5475 per share, totaling approximately $1.09 million. Following thes", "url": "https://www.stocktitan.net/sec-filings/RMD/form-4-resmed-inc-insider-trading-activity-c093ab2a0e49.html", "source_name": "Stock Titan", "published_at": "2026-07-09T11:40:40", "published_display": "09 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc. stock falls Wednesday, underperforms market", "summary": "Shares of ResMed Inc. (RMD) decreased by 6.33% to $205.84 on Wednesday, breaking a four-day winning streak. This fall occurred during a generally negative trading session, with the S&P 500 Index dropping 0.28% and the Dow Jones Industrial Average falling 1.09%.", "url": "https://www.marketwatch.com/data-news/resmed-inc-stock-falls-wednesday-underperforms-market-17a06c3d-bc6a7f9736ae", "source_name": "MarketWatch", "published_at": "2026-07-08T20:30:26", "published_display": "08 Jul 2026 20:30", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ResMed Is Dropping 5.7%: RBC Capital Maintains Outperform", "summary": "ResMed Inc. shares fell 5.7% after two Wall Street banks, RBC Capital and Wells Fargo, slashed their price targets on the medical device maker due to dimmer prospects for its sleep apnea and respiratory care products. RBC Capital maintained an Outperform rating but significantly ", "url": "https://news.alphastreet.com/why-resmed-is-dropping-5-7-rbc-capital-maintains-outperform/", "source_name": "AlphaStreet", "published_at": "2026-07-08T19:13:41", "published_display": "08 Jul 2026 19:13", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc. focuses on sleep and respiratory care. Long-term demand supports the business model.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNYi1jTlM2aUEzX3JIRHBCNnR0THJXMlprT0pRTDhGTW50YXRLMEhyN0RfX3BiZndDLUl5RHdlbTZCSklvSzVKUngxVlpMeHlvbjAzclk0WmVXb3VfeEkxQ1B2WnZpWGQxNU56TkhMSHE2NUxvY3U5aXd3Q1huVlFaUmNua01naFh2ak1UWjlMTjE0aW82V1ZxSnplZE1JUlZmb1Nhczk4YzhSXzhuMnRCelZqbUlGMnlEV0hJejZFSU1vUQ?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-08T16:36:46+00:00", "published_display": "08 Jul 2026 16:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOZTlGSTFaNjhCSklCUlkwYXhxU0I4aVNRaFRsY2pZdVlETExQaWw3U2Y2Z2I3c0FUQWIzVjJGRnNpc0Q3MU5OOFdNaWtKTHFFNGpaR0tKVHFHaTNjQzRPS1M1UjhYa2lTX1FrQ3FHbUgwRnh0bUpBckg0d2ppMjFTS0c2MmxCMVlzZlI4VzJ3?oc=5", "source_name": "Market source", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed to sell software business MatrixCare for $490 million", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNT2NvNGJFSGdUVm5fODh6ZjhUTXFOeWhXLTkxWnVaTjJ0WC1HU3hraGJNcER0SDh0T184Z2U3RzdZQ0cxaFFiVDMza2h4Z091SHdBa015N044bThMb2JrSW1hcXgtY1RleGlvd0V6c0NzNFZEZ183LUhjaGlYZWRXbVJSa09Ba0lFZXdBNDJYakd0a1d5dUpkX0kxdGZYZWxXVkNCVi1VaEQ?oc=5", "source_name": "Reuters", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Resmed (RMD) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBuTFIwN0hsQ2dWMkNIOGRJRm8yYnVHSXhobXhTUjBqRjAwZkVkOEJRa0RKREdYUXZZTVdFRjA2ZEZMcFZUVkhvX0FiMXV5RFNXOXF4by1hR1h3Q2VlZnFBSWc5b2kyX1EzZEx3cFhxWFliaElKRUVlcHdQWDRwUTA?oc=5", "source_name": "Moomoo", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Stock And 2 Blue Chip Picks Retail Investors May Be Missing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQZFRRY3FXRUJFVlk5emlLWV9OWVhQa3lIdlo3dmJVUVAzU01wTXdHZF9pMTloVVYtS29udldDcmgzM1hKVXc2Qkl5RmxEYm5ZUnNyZTgtZEdaeU95cVlmY0h4cjhkSW1ZSWw2Z20wclJXdmh4cHUwd0N0Q0dDYllmM0dFOThoSmRiNC03bDZiVFdlV1dtWlB2dnc0cmZyQ2c0MEVHM2hTT0MwSHM1UmNuUVNudlFvbVcwdWlxaHdhaXBIVUEwZUZfb2Nn0gHPAUFVX3lxTFBxd2paWUVZTEItSTlDSGh0NC1QSHBhY2lZSTREUW05TWNuVXotN0Rac0RENnBrckduT3lxTkhmSHBlUkxpcHo1YjEwRnN5bEU5S0NId01iU1dTd29JMnhmS0dab1V4U2kzcXdHa3ludjBhWE9oTGxmcUtPOFZCX0dfR19IYnQxZWR6MmE1RS1LRXdmdG43N3k3MU9IUEl0dUlTSy1rejJuc0NieXowVDZocVJkd08zX3ZKU05PdFN3XzhQUzQ4TUFOd0tzVGhrcw?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ResMed (RMD) Stock Is Trading Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNWHYxbFhKZk1JWFdDS2hLNUdURWp0R2xKbjlKTGdCTnI5ekI4SzNTd3RlRng3NERSeFB5SEs2SFdZUUhoSzJyZnNhZDJRRnUwWmJJbjRBRFpnRlVjMHdyVTM1ZmxiQVo1RHdpV2NwSWZkaGJhb0t1NnQ1cHA2ckNsQV90dGx3VlRFdmFuUDhIcDVadlJMLWJyRg?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc. focuses on sleep and respiratory care as a long-term growth story", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOLTFZQUZvWWp3NE9LS1FMWUcteUJ2aGpaQ1l0VHl4aTNiZVVxdm0xSGE3RWNUVWJIVDRVZVVid21jdVp1QndVQ2c4Q3BTc3huN2pBNERwQlgyNTJISTBud0RpRndVMTRuSzZ1VzUzQWZDY1I5ak5TZlRtQkc5ckFLU2Yzalh6eEV4bXFjbGJuTllMMWRXbTNKRGp6WllrWFR5ODlINHp3MU9TbFdxMVppOThJcHJNSHZPczFCOER0OEtYQkJBU2FFVA?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-01T16:39:31+00:00", "published_display": "01 Jul 2026 16:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Stock Looks Cheap Even As The Market Stays Cautious", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPX1FEVlZYR1A3aUctMGtJMl81Unl3VzlVREw2UVViVTl0UlMxU2NsRGVYd0dvWXMyb1pTNDV3c1NpQS1wcm5hOFMyRy1TUS1yU3ZreWt4WlVCQ00zM2FtT1F1dWhhcjhHZmZmYUU4X1lCWUFBT3pKTTdYYldHQzFJLUp4N3JhOWIyX0FKbk1zSWN4MlJsbFpyXw?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Stock Looks Reasonable After A 23% Fall", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ResMed Inc. (RMD) Stock Still a Long-Term Winner as OSA Market Expansion Continues?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQM1hBQnZIR2dLZU9XZV9JVnp2ZnQydk1JM2prTUw1MkRvT3VmbnZGdGhFSFJTbThkQTJnR1pIWVNhVUJHd3RBUy1NMWVXWGtDbjM1RUVmUVh3MkcyaUxaN09ZQjFMZzVQMWJCZVNzSnZrY0xiVXZldVNSZXZGM0Q0VV9jRlJ1ZUZxODBDUXlUV0M?oc=5", "source_name": "Market source", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Shares Downgraded: Trimmed Price Target Offers Some Comfort To Bulls", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNRFBKeE5SMy0zN2hsWGoyWUZxNEU5WUpGNjRsMkYyWGJaeDVheHlERTM3ajFFOXF5d0tIVEItZlJ6SkFHLXBZS0ZZLV9WeElpdE9vY0tBUEtOcG5vVDUzemRyV2NZRUZwSEFBSkpJcnhaaG9tTmdqd2V3VkxCaHNUQ3RqbGpmQ3dnTUFHbEd1bnB5bVJfYTEyejd4UWJDNlU5ejFDYWp3?oc=5", "source_name": "thebull.com.au", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why ResMed (RMD) Shares Are Falling Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOOWJkbkxncDFGTnI1LWprZzVTU0J3R3UwVkV2LWxCa3FTY3ByZzF6ako3Y0cyUWR5aEptNDNOcXhXQkJrRjJqS1dKcHpvZm5RWU5KYXJCV2lCNzdNQkxMT0xQdUk5dFFpVnJ6Skc1UXUwZ3lMUDYzYTh6T0NGQlo4SEVHaDF2QnlQamZ6bE5sZ1pJTURwRUNFc0tn?oc=5", "source_name": "Market source", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Stock Valuation Check After Mixed Returns And Undervaluation Signals", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQa2NqQ0xVdGU5MUxDVUlBWnFSYXJpQVFuX1RTVmZMNmQ2NDZQNUtWRDQwMW1CTFlfbHg1YTZDb1pfNVk1dzNncnVjWDZabnNoUm1EX3hKTG5rRk1SSnQzN21ZMV9EWUlkT2N6ZTBENFctUGhneFJpQS1xOWNNS2liSVo0T3lRT3d1TUZsSE16dlh4QVFDNWtjeTNZdm5vQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ResMed Inc. (RMD) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOd0FyYk1qZnliWDRRMmc0bE9XYUdpUmtVN09aVTF0c3A2b2p5Q3huR0JnOHNPMWxGeDNxdVNHVmZ4YWtmTWV3aUYzS05BTDZGaHpRUy10UUlDeHlQNExWUkc1ZVN6ckxnUWYxV0NjeXFtVEE4ZXl0R1lYTmp1MzlpZDR3OGp4UUtUMklYaTBBWW1qbDhj?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Reassess ResMed (RMD) After A 25% Share Price Slide?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPTzlaQmIyMkNsUnZhVnBhaWRiXzRyckh0SDFCc3B2M0xTYlpBSHdfMnhjWG9HYXZDbGh2MElIUnBCRmtLdDlRcjVkMkNzd3JLbGxIX1k2X0J2OXZjdGMzRTdLM0lsUHVFQmVGTjJBRWNLSEpSd1BaRkdLa3RpVWgtcEJPZ0dJWG44elA3Q0FweC01ek9KOXln?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (ASX:RMD) Q3 Results 2026: Is the ASX Healthcare Stock Back on Track?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQc3NZakEyaVpSUzZnX0htSmpOY3ViWFFBZlY5ZnI0eERxb2R0bE42bmt5ZWdRaEJPWFlZeV9OU0huNERtNjM5NkR5WG9WcDdkc2lUU2lNUTZSajhxakNrV3U4ZFJhNDlzdnBCOUhEWDFfdUtfYXY2cjZaQVhibjlQZ3Y5aXVpZ2dZVDd1ZXRVb1JRVmk0MXhBZGhPcjEwUUlNcmpkdWZNRE1SVEZIWnVN?oc=5", "source_name": "Kalkine", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc stock (AU000000RMD6): Sleep apnea and respiratory care leader posts strong growth outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQNGZ5THM5SU1TZW5Sc3N2azhsTjE5MHdleWFBS3lZamk1ZGlmbE8tSFFGNmpRVHhiMGc1T1ZwOU0tc0liODhZT3RUcWNrWDdDWnNtVERrTTBsOWc1WHpiNDllVUJFcmNGb1VUMlBCR3hMTDR1UEVfaTFOeTJjdVdvNFdoandmSDh3b2NqWGVjMG9xZVpNeGlnd3lpUWlNTXNDRC1OWXRGZnRjSkN0dm0telhjZTNPQ0xjOFFCTXhJMFRkVERnZ0M0?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-10T07:00:00+00:00", "published_display": "10 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Stock Is Down 22% in 2026: Here\u2019s Why Analysts Still Sees $256 Fair Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQMDVZWVJWWlA3RTF2dFpMNmwzTjlSVjdJdDlXRVFnSGVsTmRCaldSeHBmQXR5QmM2RVM5MnpJZjVxX0J3Sy0takpCUWRxQktnSHdlc05PYlpmYmphVjc1Tm9fLVJ5ZlJzYjRBaExmdVlZR211dUZ3cGdXaWxlOFBsZnBOc0hJVnJyNGhLN2FURWQ0LVZGbDhhM3ZBd0poR0ZzMS05Zg?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Surpasses Q3 Earnings and Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOMGFZRU5ReG52TGk2XzRoV3VhNVlwVnZNNThmVTc3eDFWZlV6SUtFUi04Y3hPUktrRTlRdEJNdVh4RW0zUmc4NENFdDZ4cTRBbXRsN0dKSGhuY1pyeFB5NDN6ZWMxYlk4MnhWVjVqeGpTTVBXbkhiQmtHajh3OXFtQV9MUGZNWXd0QzhEYnJyVmZ3RC14enpnaTktWUpyUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Resmed's Q3 Earnings on Deck: What's in Store for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQQ05lOWNMcFE2WXNCdGJCTjRTZkRkaUlDVXRzc0I3SklOal9KTGRpODZlSVRkZ1J5TWgwTWwtWDB4eFBMelI0OGNyWGVRVmVuaGV4UzhtWEE4WEdLWUtWTW9iRlpCNklNNWhNdDNvY2xBUUxqN1pxbXlCMWdET0VUZFpLbDdIRVFHckpGeUk1OGRWUElDT0lCSVBaWlpNYjBXOWFKWDhEd19DZnoyTXVSXzJoWFU?oc=5", "source_name": "TradingView", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed (RMD) Stock Trades Down, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE52UXpVc3NJY2huYndaSW8tNF90dHNMb2FYYl9WQ0kyYy1WaXpsaWhFSTVZdjc0SmVDRHNZczdEWWg4TVgxd095MVBETlJfUFFWR2Q5QjVjRGF4UUI5XzZhaXp1YnpFN0ExZU55bXlJSGZZZHhXODFTT3lqTFY0clE?oc=5", "source_name": "Market source", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock of the day: ResMed", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQbXM2V2ZOdjM5WDQ0OTlSZDVjYm4yMkRPZFZnWEFsZFpOSVdIRUcxVWQ5NDBVaE0zRW5NUE5pcC1sYmtQRjh0M3ZQSm1HT1JoRy10SExBaEs2Z0dKLXFqLUhXQVdUWDZZWUtocDliYTlNbC1VbG40VVN1bkdIa1NWUlZhbw?oc=5", "source_name": "ig.com", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Resmed's Q2 Earnings on Deck: What's in Store for the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOaXFGaWZNbHNUeFBDb2YzNXBlcXdTTEs0OXNHWXA2d1VQZmtNa2NJQ2RkUVJfTXpldVAweGNpV2pfNi1qOHZWeEFneVQxZloyNHVNVkJoZmNEMEcxdUdJdTBkcGloN2ZQX3luNllYNjJETE9WdnZaV2pYUFl3QnVveUI4RXllZi1hRzgtVVA4ZUxpaUx6a0hmelJrZ2NGZGRKTDR5ajZVOXFnMDRiYmVvcnZ1OFo?oc=5", "source_name": "TradingView", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Inc. (NYSE:RMD) is favoured by institutional owners who hold 69% of the company", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-02T08:00:00+00:00", "published_display": "02 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASX 200 healthcare stocks: ResMed, CSL, and Telix Pharmaceuticals in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQbThHc0xvdzNveVg0RlcyOWdLLXRQRGJQeU5SU0F3Q2xTalZqTmtUN2oxMUVDSVFJb3FKanR5S0M5TkVGUVI5ZllRT1VTYjQ0bkhrN01XN3p5Q0gxdEg3MkdPOERLdk9GMi1mWk00a1BVWERyLXJIaUI0WVZOSWh2V0JiSVA5VnZlYVlFVkNLT0RiOUhObm1hMFBweW81eUFhVVE?oc=5", "source_name": "ig.com", "published_at": "2025-09-23T07:00:00+00:00", "published_display": "23 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RESMED INC SEC 10-K Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNa01vb045LUtQbHNoMUxtVldSWU5KN1k1UjV1ckZfd1RtWElJOVU4VWlGbTZsUUlpV3ZvNEd6WV9wUTdNUXZFWlA3OTlacjl0dHpSWFRpenV4ZzNmaUc0RlpDdUNrUXJHUXJUQ1JpUXR5SlF0UGhlbmtwamxFVGJZMnc1RjFZNmNHQkNIYnk0ZjFyUQ?oc=5", "source_name": "TradingView", "published_at": "2025-08-08T07:00:00+00:00", "published_display": "08 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ResMed Full Year 2025 Earnings: EPS Beats Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPQk5pQlA1cFVLT2FISEFTaVdndWRhdGp5aDlkX0VadkhlN0lBMmZDOTF6czFqRkZ5Q3ZCOVlqTG9aRlpMa1o0R3ZHUnJEUGVOdXNiQnY2R3ozVHotUzdNM1lIbTdHMHVEOUpXNUtzdkpEZ1lOcFhRd3pzLVhockVFak9DZHVjWGZkZlFEQzJPRnJubVZZcV9PZU15ZlBacHRqWEJtRWhOQTZPaHFIUUJodm1Gb2ozZmRw0gG-AUFVX3lxTE4zZFdJbzBSTzIxOGppaWdfVGhkRHVsb0tCV3RCVnd1b28xVWZkcXB5ZHZzZnhqZV9lUUVLTFFWRWc1cVhUUG5OTEhmcENQQ0sxejgzemtQOW5aZ24xLV9ac29BMkRkdEdvbmZ1TFZzVWZickp2ZnVtTnREeU5YRWpuYUJaOVJRR2RVTklBTTZVMFM2TUUyWFE3WHZVUzBlUi01WUYxRElQT2VuQ3YzcW9GSVBzMWduSzdzYjJadEE?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-03T07:00:00+00:00", "published_display": "03 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 94, "total_relevant": 57, "sentiment_summary": {"positive": 15, "negative": 10, "neutral": 32, "score": 52, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 20.45, "count": 34}, {"event": "analyst", "label": "Analyst action", "weight": 5.3, "count": 9}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 9}, {"event": "macro", "label": "Macro sensitivity", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 203.87, "latest_week": "2026-07-10", "one_week_move": -2.7, "four_week_move": 4.7, "twelve_week_move": -10.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.231628, "market_dynamics_buy_signal": false, "relative_strength": -25.017099, "fair_value_gap": -6.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.615, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.7% over one week, +4.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Moomoo", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "MarketWatch", "count": 4}, {"label": "The Globe and Mail", "count": 3}, {"label": "Ad Hoc News", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "Simply Wall Street", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 57}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Analyst action", "count": 9}, {"label": "Earnings", "count": 9}, {"label": "Macro sensitivity", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "57", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "6", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.7% over one week, +4.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "ResMed Inc. stock rises Wednesday, outperforms market"}], "updated_at": "2026-07-16T16:00:38.083139+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}